Copyright © Inderes 2011 - present. All rights reserved.
  • Seneste
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Udbyttekalender
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team

Probi

Mindre end 1K følgere
Alle
Selskabspræsentationer
Selskabsmeddelelser
Eksterne analyser
ViserAlle indholdstyper
Pressemeddelelse22.7.2025, 13.00

Women's Health by Probi wins NutraIngredients-USA Award for Innovation in Women's Health

Probi
Pressemeddelelse28.5.2025, 06.37

Probi Female wins prestigious NutraIngredients Award 2025 for innovation in women's health

Probi
Pressemeddelelse7.5.2025, 00.30

First-of-its-kind: Nomura Dairy and Probi[ ]introduce probiotic-enhanced carrot juice to Japan

Probi

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto
Følgere og notifikationer om fulgte virksomheder
Analytikerkommentarer og anbefalinger
Værktøj til at sammenligne aktier og andre populære værktøjer
Opret konto
Selskabsmeddelelse3.2.2025, 08.20

Delisting of Probi

Probi
Selskabsmeddelelse20.1.2025, 21.01

Notice of Extraordinary General Meeting in Probi AB (publ)

Probi
Selskabsmeddelelse20.1.2025, 21.00

Probi applies for delisting and convenes an Extraordinary General Meeting

Probi
Selskabsmeddelelse9.1.2025, 07.00

Probi postpones year-end report 2024

Probi
Selskabsmeddelelse13.12.2024, 16.17

Statement from the independent bid committee of Probi in relation to the public takeover offer by Symrise

Probi
Selskabsmeddelelse20.11.2024, 06.19

Probi's Board comments on Symrise's public takeover offer

Probi
Selskabsmeddelelse13.11.2024, 10.00

Probi CFO departure

Probi
Pressemeddelelse23.10.2024, 11.00

Probi Launches Clinically-Supported Probiotic Solution for Metabolic Health at SupplySide West 2024

Probi
Eksterne analyser23.10.2024, 05.24

Probi: Managing costs well in Q3 - ABG

Miss on Q3 sales (-12%) and EBITDA (-10%) vs ABGSCe China faced headwinds due to macroeconomic factors EBITDA revised down by 2-3% for '24e-'26e Encouraging B2C sales efforts in the Nordics Probi reported a soft Q3'24 with sales amounting to SEK 143....

Probi
Probi, Audiocast with teleconference, Q3'24
Videopræsentation22.10.2024, 08.00

Probi, Audiocast with teleconference, Q3'24

Probi
Selskabsmeddelelse22.10.2024, 06.00

Probi: Q3 2024: Tangible improvement in operations

Probi
Pressemeddelelse17.10.2024, 06.50

Presentation of Probi's Q3 Report 2024

Probi
Pressemeddelelse16.10.2024, 11.30

Probi partners with Global BHP BrainTrust and the FINGERS Brain Health Institute to counteract dementia

Probi
Pressemeddelelse10.10.2024, 07.00

Nordic launch of Probi Sense - a unique dietary supplement for the mental capacity

Probi
Pressemeddelelse24.9.2024, 11.00

New study strengthens Probi[ ][®]s L. plantarum HEAL9[®] strain in cognitive function

Probi
Eksterne analyser17.7.2024, 06.29

Probi: FY'24e marks a transition to a promising future - ABG

- Beat on Q2 sales (+3%) and EBITDA (+24%) vs ABGSCe - EBITDA up 2% for '24e and 1% for '25e - Our comprehensive analysis indicates a promising long-term outlook Americas and EMEA progressed well in Q2 Probi reported a strong Q2'24 driven by growth in...

Probi
Probi, Audiocast with teleconference, Q2'24
Videopræsentation16.7.2024, 08.00

Probi, Audiocast with teleconference, Q2'24

Probi
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.